About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Feasibility of a Method for Analysis of Alzheimer´s Disease Specific Proteins in Nasal Secretion

NCT05791552·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Marion San Nicoló, MD
CONTACT
+49892302680 marion.sannicolo@noselab.com
Mareike Haack, MD
CONTACT
+49892302680 mareike.haack@noselab.com

Lead

Noselab GmbH

Age

18–any

Sex

ALL

Healthy volunteers

Accepted

You may be eligible if

Group A Patient WITH cognitive impairment and no nasal pathologies. CSF analysis is planned or results are already available
Group B Patient WITHOUT cognitive disorder and without pathologies in the nasal area

You may not be if

Presence of an obstructing nasal cavity disease
Patient suffers from an acute upper respiratory tract infection (putrid rhinorrhea)
Inability to give consent

The record

StatusUnknown

PhaseNot applicable

Taking part500

StartedFeb 2022

UpdatedMar 30, 2023

Conditions

Nasal Secretion Alzheimer Disease Brain Nose Interface

Where1

Noselab GmbH
München, Bavaria, Germany